Trevi Therapeutics earnings and fresh shelf registration in focus

Trevi Therapeutics (TRVI) reported a second quarter 2026 net loss of US$17.8 million, wider than the US$12.3 million loss a year earlier, and filed a US$149.2 million common stock shelf registration.

Trevi Therapeutics' share price has moved from short term softness, with a 1 month share price return down 3.1%, to strong longer term momentum, including a 3 month share price return of 39.6% and a very large 5 year total shareholder return, as investors weigh deeper losses and the fresh US$149.2 million shelf against future funding options.

If Trevi Therapeutics has you rethinking your exposure to fast moving healthcare names, this could be a good moment to scan for other opportunities in 40 healthcare AI stocks

Bulls point to Trevi Therapeutics’ strong multi year share price gains and pipeline potential. Bears focus on widening losses and the US$149.2 million shelf. The key question is which side the current valuation leans toward as the next step.

Most Popular Narrative: 34.4% Undervalued

Trevi Therapeutics' most followed narrative points to a fair value of $28.18 per share compared with the last close at $18.48, which implies a clear gap that investors are trying to explain.

Approximately US$188 million in cash, cash equivalents and marketable securities at year end 2025 with an indicated runway into 2028 funds top line data across key IPF, non IPF ILD and refractory chronic cough studies. This limits near term financing pressure and can support more controlled decision making around future capital structure, share count and potential earnings per share.

Want to understand why this narrative still reaches a higher fair value despite forecasts for continued losses and no near term revenue? The story leans on aggressive future revenue build, a step change in margins and a valuation multiple that sits far above typical sector levels.

Result: Fair Value of $28.18 (UNDERVALUED)

However, this Trevi Therapeutics narrative still leans heavily on a single drug, and any clinical delay or extra capital raise could quickly challenge those fair value assumptions.

Another view on Trevi Therapeutics using market multiples

The earlier narrative leans on long term earnings forecasts and high future P/E assumptions to call Trevi Therapeutics undervalued. A simple cross check using today’s P/B ratio paints a tougher picture. TRVI trades at 8.2x book value compared with 2.5x for the wider US Pharmaceuticals industry and a peer average above 550x. That gap suggests investors already pay a premium versus the sector while still accepting a discount to the highest risk peers. The key question is whether that mix of premium and discount feels like a comfortable place for new money.

Next Steps

After weighing both the bullish and bearish points around Trevi Therapeutics, it helps to look past the headline narrative and inspect the underlying risk flags directly. To round out your view and stress test your own thesis against the concerns other investors are watching, take a close look at these 4 important warning signs.

Looking for more investment ideas beyond Trevi Therapeutics?

Once you have a view on Trevi Therapeutics, do not stop there. Cast a wider net so you are not relying on a single story.

• Target potential mispricing by scanning 53 high quality undervalued stocks that combine solid fundamentals with a price that may not fully reflect their underlying financial strength.
• Prioritise resilience by checking 80 resilient stocks with low risk scores that score well on financial health and show fewer red flags on balance sheets and cash flows.
• Get ahead of the crowd by reviewing a screener containing 19 high quality undiscovered gems before they appear on every investor’s radar and competition for entry prices intensifies.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.